Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254596 | 0.94 | SRC (0.39) | HTR2ASRCHTR2CABCB11CYP1A2 | |
| SCHEMBL254595 | 0.92 | SRC (0.46) | HTR2ASRCFFAR4RAB9AATM | |
| SCHEMBL14368286 | 0.90 | SRC (0.40) | HTR2ASRCHTTHTR1ADRD2 | |
| SCHEMBL258000 | 0.89 | HTR2A (0.41) | HTR2ASRCHTR2CABCB11CYP1A2 | |
| SCHEMBL254612 | 0.87 | SRC (0.46) | HTR2ASRCHTR2CABCB11CYP1A2 | |
| SCHEMBL257998 | 0.86 | SRC (0.53) | SRCHTTHTR1ADRD2HTR7 | |
| SCHEMBL254384 | 0.86 | SRC (0.44) | HTR2ASRCHTR2CABCB11CYP1A2 | |
| SCHEMBL254618 | 0.85 | RAB9A (0.39) | HTR2ASRCHTTFFAR4RAB9A | |
| SCHEMBL253935 | 0.85 | HTR2A (0.43) | HTR2ASRCHTR2CABCB11CYP1A2 | |
| SCHEMBL255045 | 0.84 | SRC (0.40) | HTR2ASRCHTR2CABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2558085-B1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | ATHENEX INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-7968574-B2 | Biaryl compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968574-B2 | Biaryl compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110065705-A1 | Compositions and Methods of Treating Cell Proliferation Disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2011-03-17 | — | — | US | disclosed |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2008127728-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | HTR2A 2478/4885SRC 116/4885HTR2C 2294/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | HTR2A 3446/4885SRC 76/4885HTR2C 3225/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | HTR2A 3446/4885SRC 76/4885HTR2C 3225/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | HTR2A 3347/4885SRC 112/4885HTR2C 2643/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | HTR2A 3446/4885SRC 76/4885HTR2C 3225/4885 |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | MKI67, CCNC, CCNA1 | HTR2A 3566/4885SRC 430/4885HTR2C 3724/4885 |
| US-20110065705-A1 | Compositions and Methods of Treating Cell Proliferation Disorders | MKI67, CCNC, CCNA1 | HTR2A 3566/4885SRC 430/4885HTR2C 3724/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | HTR2A 3566/4885SRC 430/4885HTR2C 3724/4885 |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K3, MAP3K6 | HTR2A 3347/4885SRC 112/4885HTR2C 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.